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background:  The clinical value of prasugrel in ACS patients with high platelet reactivity (HPR) is unknown. We aimed to investigate the impact of 
administration of prasugrel or high-dose clopidogrel based on platelet function testing in acute coronary syndrome (ACS) patients undergoing PCI.
methods: Clopidogrel pretreated ACS patients undergoing successful PCI were enrolled in a single-center, prospective registry. Platelet function was 
measured 12-36 hours after PCI with the Multiplate platelet function device. Patients with HPR (>46U) were switched to prasugrel or were treated 
with high-dose clopidogrel, while those without HPR continued 75 mg clopidogrel. High-dose clopidogrel was administered as repeated loading 
doses of 600 mg up to 4 times, proposed by Bonello and colleagues.
results: Between September 2011 and August 2012, 741 consecutive patients were enrolled of whom 219 (30%) had HPR. Although platelet 
reactivity significantly decreased in response to treatment adjustments in groups with HPR, prasugrel showed significantly more potent platelet 
inhibition than high-dose clopidogrel both after loading dose and the during maintenance phase (p<0.0001). Compared to patients without HPR, the 
risk of all-cause death, myocardial infarction, stent thrombosis or stroke at one year was significantly higher in the high-dose clopidogrel group (HR: 
2.27[1.45-3.55], p<0.0001), while patients switched to prasugrel had similar outcomes (HR: 0.90[0.44-1.81], p=0.76). BARC type 3/5 bleeding 
was also higher with high-dose clopidogrel (HR: 2.09[1.05-4.17], p=0.04), but not for patients switched to prasugrel (HR: 0.45, [0.11-1.91], 
p=0.28). In multivariate model, HPR with high-dose clopidogrel, but not with prasugrel was an independent predictor of the composite ischaemic 
endpoint (HR: 1.90[1.17-3.08], p=0.01).
Conclusions: Switching ACS patients with HPR to prasugrel reduces thrombotic and bleeding events to a level similar to those without 
HPR; however, using high-dose clopidogrel results in higher risk for both thrombotic and bleeding complications.
